IDH1 and acute myeloid leukemia: In the past three years, the FDA has approved two mutant IDH (mutIDH) inhibitors for relapsed or refractory AML harboring IDH mutation, namely enasidenib (AG-221)—which is a first-in-class oral selective inhibitor of the mutIDH2 enzyme—and ivosidenib (AG-120)-targeting mutIDH1 [93].